ABSTRACT
Background@#The morphology of hair regrowth in alopecia areata (AA) patches could be classified into four types, namely diffuse, irregular, marginal, and targetoid patterns, according to the DIMT classification. However, factors affecting hair regrowth patterns have not been investigated. @*Objective@#We investigated whether the DIMT-classified hair regrowth patterns of AA patches are associated with treatment modality and patch size. @*Methods@#We conducted a retrospective, cross-sectional study of 152 AA patches with hair regrowth. @*Results@#The associations between the diffuse pattern and patch size >2 cm (p=0.006;odds ratio [OR]: 0.36, 95% confidence interval [CI]: 0.17~0.74), between the irregular pattern and triamcinolone acetonide intralesional injection (p2 cm (p=0.028; OR: 2.50, 95% CI: 1.10~5.68) were statistically significant. @*Conclusion@#Treatment modalities and patch size are the factors affecting hair regrowth patterns in AA patches.
ABSTRACT
Background@#Contact immunotherapy with diphenylcyclopropenone is one of the first-line treatments for extensive alopecia areata, despite its adverse effects (AEs). @*Objective@#This study aimed to investigate whether a modified contact immunotherapy treatment protocol can safely promote hair regrowth in children. @*Methods@#Children with alopecia areata who were treated with modified contact immunotherapy with diphenylcyclopropenone were retrospectively reviewed. All patients were sensitized with 0.1% diphenylcyclopropenone and began treatment at subsequent increasing concentrations. The efficacy, AEs, and demographic factors were evaluated. @*Results@#A total of 32 patients, aged 9 to 17 years (mean age, 14.6 years), were included in the study. The mean disease duration was 26.8 months. Ten (31.3%) and 11 patients (34.4%) showed complete and partial responses, respectively. No AEs were observed after the sensitization. During treatment, 13 patients (40.6%) did not experience any AEs. Sixteen patients (50.0%) showed mild to moderate pruritus, and only three patients (9.4%) had severe pruritus. However, all AEs were well controlled. @*Conclusion@#A modified diphenylcyclopropenone treatment protocol with subclinical sensitization could induce a favorable therapeutic response and fewer AEs in children.
ABSTRACT
Background@#Pediatric alopecia areata (AA) can affect the quality of life (QoL) of patients and their family members. Research on the QoL and burden on family members in pediatric AA is limited. @*Objective@#This nationwide multicenter questionnaire study described the QoL and burden of the family members of patients with pediatric AA. @*Methods@#This nationwide multicenter questionnaire study enrolled AA patients between the ages of 5 and 18 years from March 1, 2017 to February 28, 2018. Enrolled patients and their parents completed the modified Children’s Dermatology Life Quality Index (CDLQI) and the modified Dermatitis Family Impact (mDFI). The disease severity was measured using the Severity of Alopecia Tool (SALT) survey scores. @*Results@#A total of 268 patients with AA from 22 hospitals participated in this study. Our study found that the efficacy and satisfaction of previous treatments of AA decreased as the severity of the disease increased. The use of home-based therapies and traditional medicines increased with the increasing severity of the disease, but the efficacy felt by patients was limited. CDLQI and mDFI scores were higher in patients with extensive AA than those with mild to moderate AA. The economic and time burden of the family members also increased as the severity of the disease increased. @*Conclusion@#The severity of the AA is indirectly proportional to the QoL of patients and their family members and directly proportional to the burden. Physicians need to understand these characteristics of pediatric AA and provide appropriate intervention to patients and their family members.
ABSTRACT
no abstract available.
ABSTRACT
Background@#Chrysanthemum zawadskii (CZ) belongs to the genus Chrysanthemum, also known as ‘Gu-Jeol-Cho’ in Korea. CZ has been used as herbal remedy to manage cough, hypertensive disorders, pharyngitis, bronchitis, gastroenteritis, pneumonia, bladder diseases and common cold. However, its effect on hair growth has not been documented. @*Objective@#The aim of present study was to elucidate the beneficial effects of CZ on hair growth. @*Methods@#Proliferation of follicular dermal papilla (DP) cells from human scalp skin was evaluated by MTT assay. The expression of various molecules in DP cells was checked by western blot assay. Effect of CZ extract on the hair growth was evaluated by hair organ culture and C57BL/6 mice model. @*Results@#Cultivation of DP cells with CZ extract increased cellular proliferation, increased expression of phosphorylated protein kinase B (p-Akt), p-ERK, B-cell lymphoma 2, and decreased expression of Bax. Treatment of human hair follicles with CZ extract significantly enhanced hair growth. Additionally, CZ markedly shortened telogen period, increased anagen transformation and stimulated hair growth in the animal study. @*Conclusion@#These results suggest that CZ extract has an effect of promoting hair growth and may therefore be a useful a therapeutic remedy for preventing hair loss.
ABSTRACT
BACKGROUND: Klotho protein plays a pivotal role in aging regulation. However, it is unclear whether klotho is expressed in human hair follicles and is correlated with hair growth. OBJECTIVE: The purpose of this study was to determine the expression pattern and role of klotho in human hair follicles. METHODS: We examined the klotho expression patterns in human hair follicles from young and aged donors. Furthermore, we examined the functional roles of klotho on human hair growth using klotho siRNA and klotho recombinant protein. RESULTS: Interestingly, klotho was expressed in human hair follicles at both gene and protein levels. In hair follicles, prominent klotho expression was mainly observed in the outermost regions of the outer root sheath and hair bulb matrix cells. Quantification of klotho protein expression in young and aged donors showed that klotho expression decreased with aging. In human hair follicle organ culture, klotho silencing promoted premature catagen induction and inhibited human hair growth. Otherwise, klotho protein prolonged human hair growth. CONCLUSION: These results indicate that klotho might be an important regulatory factor for human hair growth and hair cycle change.
Subject(s)
Humans , Aging , Hair Follicle , Hair , Organ Culture Techniques , RNA, Small Interfering , Tissue DonorsABSTRACT
BACKGROUND: Androgenetic alopecia (AGA) has a negative impact on self-image and decrease in quality of life. However, relatively few men have sought treatment for AGA. Improvement in treatment willingness is important for maintaining long-term management in patients with AGA. OBJECTIVES: We aimed to identify the prevalence of patients' perception of hair loss and evaluate various factors that affect the treatment willingness in patients with AGA. METHODS: We conducted a population-based cross-sectional survey of 503 patients with AGA (329 men, 174 women). We collected the various demographic data, family history of AGA, history of past treatment, self-perception of hair loss and treatment willingness using structured questionnaires. Then, we provided the knowledge about AGA to the half of subjects and compared the treatment willingness between educated group and nond-educated group. RESULTS: Two-hundred and forty-seven out of 503 patients (49.1%) did not have illness perception and 262 out of 503 patients (52.1%) did not have treatment willingness in future. The patients with perception of hair loss, accurate information on hair loss and severe hair loss showed 1.745-fold, 1.700-fold, and 2.078-fold higher tendency of receiving treatment in future. CONCLUSION: Our findings imply that patients with perception and greater understanding of AGA tend to pursue treatment for AGA. Thus, these elements should be taken into account when treating patients. In addition, emphasis on education is needed to increase public awareness of the AGA.
Subject(s)
Humans , Male , Alopecia , Cross-Sectional Studies , Education , Hair , Prevalence , Quality of Life , Self ConceptABSTRACT
BACKGROUND: Alopecia areata (AA) affects anagen hair follicles resulting in non-scarring hair loss. Since its introduction, superficial cryotherapy has been used as one of the meaningful treatment modalities for AA. OBJECTIVE: The purpose of this study is to clarify the therapeutic efficacy and safety of superficial cryotherapy for treatment of AA. METHODS: In 19 patients with multiple bilateral AA patches on their scalp, superficial cryotherapy was performed on the right side, every 2 weeks. Prednicarbate 0.25% solution was applied twice a day to both the treated and the control sides. Clinical improvement was estimated using the Severity of Alopecia Tool (SALT) score by 3 different dermatologists, along with the changes in terminal and vellus hair count and hair thickness analyzed by phototrichogram. RESULTS: After 4 months of treatment, mean terminal hair count on the right scalp was 1.6-fold increased (p=0.005), while mean terminal hair count on the left scalp showed no significant change (110.1% increase, p=0.285). Mean SALT score decrease on the right was 4-fold greater than that on the left (40.7% and 9.6%), without statistical significance (p=0.282). Mean vellus hair count and mean hair thickness did not show significant changes after superficial cryotherapy. No remarkable adverse event was observed. CONCLUSION: Superficial cryotherapy is an efficacious treatment modality with advantages of simplicity and noninvasiveness. It can be considered as a meaningful therapeutic modality for AA, especially when the disease status is limited to minimal to mild, or the conventional AA treatment is not applicable.
Subject(s)
Humans , Alopecia Areata , Alopecia , Cryotherapy , Hair , Hair Follicle , Prospective Studies , ScalpABSTRACT
Vulvar vestibular papillomatosis (VVP) is a benign condition that can be viewed as the female equivalent of male pearly penile papules. Clinically, VVP is quite often misdiagnosed as condyloma acuminatum. As opposed to condyloma, VVP lesions arise from a distinct mucosal base, match the color of the surrounding mucosa, show symmetrical distribution, and are limited to the inner aspect of the labia minora. Although VVP is quite well known in the gynecological field, this disease entity is not commonly recognized in dermatology settings. Furthermore, a literature search for VVP revealed only nine reports in dermatological journals including one report from Korea. Therefore, through our report we wish to create awareness among dermatologists regarding the occurrence of this frequent but often ignored entity. Recognizing and understanding that papillomatosis of the vulvar vestibule is a normal variant will help dermatologists to avoid incorrect diagnosis and repeated unnecessary treatment.
Subject(s)
Female , Humans , Male , Dermatology , Diagnosis , Korea , Mucous Membrane , PapillomaABSTRACT
BACKGROUND: A variety of agents have been used to treat female pattern hair loss (FPHL), including topical minoxidil, topical 17α-estradiol, oral anti-androgen agents, and mineral supplements. Compared with these single agent regimens, combination therapies could be a better therapeutic option in expectation of superior treatment outcome. OBJECTIVE: This study was designed to determine the efficacy of a combination therapy consisting of topical 0.025% 17α-estradiol and 3% minoxidil in Korean patients with FPHL. METHODS: Therapeutic efficacy was evaluated in 34 women who applied topical 0.025% 17α-estradiol and 3% minoxidil once daily for more than 6 months. Phototrichogram analysis was performed before and after therapy. The efficacy was evaluated with respect to total hair count, hair caliber (as assessed by phototrichogram analysis), and photographic assessment. RESULTS: Total hair count and hair caliber both increased from baseline to 6 months in patients treated with the combination therapy of topical 0.025% 17α-estradiol and 3% minoxidil (p<0.001). Photographic assessment also revealed significant disease improvement, thus supporting the therapeutic efficacy. CONCLUSION: A combination therapy consisting of topical 0.025% 17α-estradiol and 3% minoxidil can be tried as an effective treatment for FPHL.
Subject(s)
Female , Humans , Alopecia , Hair , Miners , Minoxidil , Retrospective Studies , Treatment OutcomeABSTRACT
No abstract available.
Subject(s)
Cluster Headache , Erythema Multiforme , Erythema , Herpes SimplexABSTRACT
BACKGROUND: Androgenetic alopecia (AGA) is characterized by patterned hair loss that typically develops in the third to fourth decade of life. Recently, several studies have reported that medical comorbidities such as coronary artery disease and metabolic syndrome are related with early-onset (before the age of 36 years) AGA, although many of the findings are controversial. OBJECTIVE: We investigated the medical comorbidities and serologic test results of patients with AGA who were aged less than 36 years, and compared them with age-matched controls. METHODS: The medical records of 810 patients with AGA and 227 control subjects who visited the Dermatology Clinic at Yonsei University Wonju Severance Christian Hospital between 2003 and 2012 were retrospectively reviewed. RESULTS: Patients from the early-onset AGA group and controls showed no statistically significant differences in their medical comorbidities, average results of serologic tests, and probabilities of having abnormal laboratory results, except for aspartate aminotransferase levels. CONCLUSION: We observed no significant relationship between early-onset AGA and medical comorbidities in the Korean population. Further case-control prospective studies are warranted to evaluate the precise relationship.
Subject(s)
Humans , Alopecia , Aspartate Aminotransferases , Case-Control Studies , Comorbidity , Coronary Artery Disease , Dermatology , Hair , Medical Records , Prospective Studies , Retrospective Studies , Serologic TestsABSTRACT
BACKGROUND: Androgenetic alopecia (AGA) is characterized by patterned hair loss that typically develops in the third to fourth decade of life. Recently, several studies have reported that medical comorbidities such as coronary artery disease and metabolic syndrome are related with early-onset (before the age of 36 years) AGA, although many of the findings are controversial. OBJECTIVE: We investigated the medical comorbidities and serologic test results of patients with AGA who were aged less than 36 years, and compared them with age-matched controls. METHODS: The medical records of 810 patients with AGA and 227 control subjects who visited the Dermatology Clinic at Yonsei University Wonju Severance Christian Hospital between 2003 and 2012 were retrospectively reviewed. RESULTS: Patients from the early-onset AGA group and controls showed no statistically significant differences in their medical comorbidities, average results of serologic tests, and probabilities of having abnormal laboratory results, except for aspartate aminotransferase levels. CONCLUSION: We observed no significant relationship between early-onset AGA and medical comorbidities in the Korean population. Further case-control prospective studies are warranted to evaluate the precise relationship.